Literature DB >> 2294542

Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody.

L M Lamki1, Y Z Patt, M G Rosenblum, L J Shanken, L B Thompson, S A Schweighardt, J M Frincke, J L Murray.   

Abstract

Metastatic colorectal cancer was detected with stabilized F(ab')2 fragments of ZCE-025, an anti-carcino-embryonic antigen (CEA) monoclonal antibody (MoAb). The fragments were prepared by cross-linking Fab' with a bifunctional cross-linking agent, bis-(maleimido)methyl ether. The authors labeled 2 mg of ZCE-025 with 5 mCi (185 MBq) of indium-111 and injected the material intravenously, either alone or with unlabeled F(ab')2, into 16 patients. Lesion detection, pharmacokinetics, and relative body distribution were evaluated and compared with those of the intact immunoglobulin (IgG1) antibody. Stabilized F(ab')2 fragments were more useful than the intact antibody in detection of lesions: Overall sensitivity of F(ab')2 fragments for all the patients was 79.4%, whereas overall sensitivity of the intact IgG1 antibody was 32%. This anti-CEA-stabilized F(ab')2 fragment may be a powerful diagnostic tool that can achieve higher sensitivity at smaller protein doses than the intact IgG1 antibody.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294542     DOI: 10.1148/radiology.174.1.2294542

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Immunoscintigraphy of colorectal cancer using 111In-labeled monoclonal antibody to mucin.

Authors:  H Sakahara; H Onodera; M Shirato; Z Yao; G Ohshio; H Kobayashi; M Hosono; S Yano; H Nakada; M Imamura
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

2.  Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.

Authors:  C F Molthoff; H M Pinedo; H M Schlüper; H W Nijman; E Boven
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.